Diabetes represents a significant public health issue in the U.S. It affects more than 30 million Americans, including around 7.2 million who are undiagnosed. Additionally, there are close to 1.5 million new cases diagnosed annually, and projections suggest the number of those impacted by the disease will continue to grow.
Diabetes treatment has improved dramatically over the years, with the availability of a range of insulin therapies more closely resembling insulin released naturally in the body as well as other antidiabetic medicines that help patients more effectively manage their condition. The options available today help meet a wide range of unmet needs, providing patients with the tools necessary to stay adherent and healthy—saving costs throughout the health care system. Yet even with these advances, diabetes remains a complex disease to successfully manage and treat.
A new report released today reveals tremendous promise in the diabetes pipeline with 167 innovative new treatments in development for type 1 and type 2 diabetes and related conditions.
As PhRMA President and CEO Stephen J. Ubl highlights in the report, “Researchers and scientists are working on cutting-edge treatments that will make managing diabetes easier, and we are fighting for ways to make these innovations more affordable for patients.”
The 167 innovative medicines in development for type 1 and type 2 diabetes and related conditions include:
- 77 medicines for type 2 diabetes: In type 2 diabetes, which comprises up to 95 percent of diagnosed diabetes cases, the body is resistant to the action of insulin. To combat this resistance, the pancreas makes even more insulin until it fails to produce enough insulin to overcome the resistance, causing blood glucose levels to be higher than normal.
- 32 medicines for type 1 diabetes: Type 1 diabetes, which comprises about 5 percent of diagnosed diabetes cases, is an autoimmune disease where the body does not produce insulin as a result of the immune system attacking the insulin-producing cells of the pancreas. It is usually diagnosed in children and young adults and requires lifelong insulin treatment for survival.
- 68 medicines for diabetes-related conditions: These include chronic kidney disease due to diabetes (diabetic nephropathy), painful diabetic neuropathy, diabetic macular edema and diabetic gastroparesis.
The 167 medicines in development for diabetes and related conditions represent a heightened understanding of the unique circumstances of each patient and help pave the way for a more promising future for disease treatment.
Despite continuous advances in diabetes treatments, too many patients struggle to afford their insulin and other medicines at the pharmacy counter. Even though prices for insulin after discounts and rebates have fallen in recent years, these negotiated savings are often not shared with patients, resulting in patients with diabetes paying higher out-of-pocket costs for their insulin than their insurer. The biopharmaceutical industry is committed to improving patient access and affordability for medicines, and ensuring treatments meet the needs of all diabetes patients.
For more information on the facts of diabetes, visit PhRMA.org/Diabetes.
Andrew Powaleny
Andrew Powaleny is the Deputy Vice President of Public Affairs at PhRMA, where he leads communications on scientific, regulatory and intellectual property issues, highlighting the biopharmaceutical industry’s efforts in developing innovative medicines and vaccines while promoting an environment that encourages necessary risk-taking. For five years starting in 2019, he launched and led PhRMA’s grassroots initiative, Voters for Cures, bringing patients and caregivers together to advocate for access to medicine and biopharmaceutical innovation. He also co-founded and co-chaired PRIDE Umbrella, a resource group for LGBTQ+ individuals. Prior to joining PhRMA in 2015, Andrew worked as a communications consultant in Washington, D.C., and as Deputy Press Secretary for the U.S. House Committee on Energy and Commerce under Chairman Fred Upton. He holds a degree in public policy and government from Eastern Connecticut State University, with a minor in music. Outside of work, Andrew enjoys exercise, musical theater and mentoring college students through The Fund for American Studies alumni association.
Andrew Powaleny
Celebrating advances in diabetes research
The Patient Perspective: Vaccines
New Report: Tackling chronic conditions with preventive treatment
Did the administration consider the importance of blood clot medicines to patients in the price setting process?
Did the administration consider the value of innovative diabetes medicines in price setting process?
New Report: Vaccines continue to drive improved health outcomes
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
What recent rhetoric on the cost of diabetes and anti-obesity medicines gets wrong
New Report: 1,600 cancer treatments and vaccines in clinical development
New calculator demonstrates how improved adherence to anti-diabetic medicines can benefit people in Medicaid
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
4 key facts on medicine prices and spending
Support for continued progress is critical for pediatric drug development
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
State policymakers can protect American innovation and help Americans live longer, healthier lives
Recognizing National Glaucoma Awareness Month
New Report More than 160 medicines in development for mental illness
ICYMI: Cancer death rate continues to decline due to treatment advances
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
New Report: Nearly 800 medicines in development to treat chronic conditions
Recognizing National Sickle Cell Awareness Month
Insulin and reconciliation
Potential gene therapies bring hope to patients with sickle cell disease
Gene therapies can reduce treatment burden and costs for patients with blood disorders
Report: More than 500 medicines in development to treat disorders of the blood
Report: More than 600 medicines in development for diseases affecting women
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
New Report: Nearly 800 new medicines in development to treat rare diseases
Guest post: Continued research and development is critical for ALS patients and families
New report shows more than 260 medicines in development to fight neurodegenerative diseases
3 factors impacting medication adherence for patients with diabetes
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
New insulin report highlights how incentives benefit middlemen, harm patients
Report: More than 1,300 medicines and vaccines in development to help fight cancer
Sharing rebates can improve access to medicines and increase health equity
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
New report explores setbacks that bring future cancer success stories
What scientific experts are saying about vaccine safety
New report shows nearly 260 vaccines in development, including dozens for COVID-19
Nearly 400 cell and gene therapies in development to target a broad range of diseases
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
Guest post: H.R.3 is the wrong approach to help patients like me
Guest post: Sharing discounts and rebates is the right thing to do
Nearly 140 medicines in development to treat mental illness
New report finds 15 new oncology therapies launched last year
Clinical Trials Awareness Week: Celebrating innovation in clinical research
Event: New era of medicine comes to Capitol Hill
Minority health matters
New report shows nearly 20 innovative medicines in development for sickle cell disease
Five key facts about the market for insulins
130 medicines in development for asthma, allergies and other respiratory diseases
130 medicines in development for asthma, allergies and other respiratory diseases
Putting 2018 medicine approvals in context
Six key facts about the market for insulins
New report shows nearly 300 cell and gene therapies in development
World AIDS Day 2018: Hope for the future
New report shows more than 300 skin disease medicines in development
New report details the setbacks and challenges to Alzheimer’s research
Disrupting Alzheimer's
Ask About Adherence: New study finds one-third of newly diagnosed diabetic patients aren’t starting treatment
Aspen Spotlight Health: Discussing the forefront of innovation
Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
Reality check: Value-based contracts are good for patients
A new era in Alzheimer’s innovation
New report shows over 500 medicines in development for neurological disorders
Guest post: Advancing healthy hearts for patients
Rare Disease Day: Unmet need inspires innovation
New report shows 200 medicines in development for heart disease and stroke
Ask About Adherence: Private-sector collaboration can lead to savings and care improvement
ICYMI: Why 2017 medicine approvals matter
World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation
New report shows better diabetes management saves money and improves patient outcomes
New report and event examine the new era of vaccines
A new era in cancer
2017 Research & Hope Awards honor innovators in mental health
How biopharmaceutical collaboration is driving a new era of medicine
Protect your health: Important disaster preparedness tips for Harvey and Irma
Medicare Monday: Strengthening access to vaccines for seniors
Putting the bio in biotech: How Bay Area minds are powering biopharmaceutical innovation
Finding cures for incurable diseases
New report portrays flourishing pipeline
Going boldly together: New advancements and new anniversaries
More than 50 medicines and vaccines in development for HIV infection, treatment and prevention
Examining the brain in The New Era of Medicine
Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines
More than 240 immuno-oncology treatments in development to fight cancer
A New World of Medicine: New GOBOLDLY ads showcase groundbreaking scientific advancements
ICYMI: The New Era of Medicine initiative spotlights genomics in NYC
A new era in genomics
ICYMI: New era of medicine initiative kicks off in Boston
Exploring the new era of medicine
Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
VIDEO: PhRMA CEO joins CNBC’s Squawk on the Street to discuss industry campaign #GOBOLDLY
The 20-year journey yielding a new weapon against cancer
Significant progress fighting cancer: Death rate has dropped 25 percent
3 things to know about 2016 drug approvals
New report shows more than 160 medicines in development for diabetes and related conditions
New Era of Medicine
Diabetes
Medicines in Development
New report shows more than 160 medicines in development for diabetes and related conditions
New report shows more than 160 medicines in development for diabetes and related conditions